Follow Us
© 2026 Arizent. All rights reserved.
Come renewal season, employers tend to focus their health benefit strategies on the usual suspects: increasing costs of prescription drugs, chronic health conditions like cancer and diabetes, and the growing demand for mental health services.
What they haven’t planned for is the explosion of specialty infusion drugs, which is quietly (until now), but significantly impacting the costs of employee health plans.
Rob LaHayne is the CEO and co-founder of Leap Health, a new platform providing infusion therapy with at-home, transparent pricing, and major cost savings for employers and patients.
For reprint and licensing requests for this article, click here.
MetLife’s president of U.S. business shares why improving employees’ benefits literacy results in them making smarter choices for their health and financial wellness.
Employers face another steep rise in healthcare expenses in 2027, prompting a closer look at GLP-1 coverage, pharmacy spending and high-cost conditions.
Public sectors are approaching chronic disease support out of necessity, leading to benefits that build a stronger workforce.
The health and welfare leader and 2026 Excellence in Benefits honoree is guiding the bank in navigating them all.
Collaboration between employers, brokers and third-party administrators will be essential to developing customized, cost-effective and employee-friendly solutions.
